中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.031 seconds)

    Methods and compositions for RNA-guided treatment of HIV infection
    43.
    发明授权
    Methods and compositions for RNA-guided treatment of HIV infection 有权

    公开(公告)号：US11298411B2

    公开(公告)日：2022-04-12

    申请号：US15884427

    申请日：2018-01-31

    Applicant: Temple University of the Commonwealth System of Higher Education

    Inventor： Kamel Khalili ,  Wenhui Hu

    IPC: A61K38/46 ,  C12N15/11 ,  A61K48/00 ,  A61K9/00 ,  A61K35/12 ,  A61K45/06 ,  C12N7/00 ,  C12N9/22

    Abstract: A method of treating a subject having a retroviral infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the retrovirus, and eradicating the retroviral infection. A method of immunizing a subject at risk of retroviral infection, by administering a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of a retrovirus to the subject, and preventing retroviral infection in the subject.

    METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
    44.
    发明申请
    METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION 有权

    公开(公告)号：US20210252114A1

    公开(公告)日：2021-08-19

    申请号：US17068999

    申请日：2020-10-13

    Applicant: Temple University of The Commonwealth System of Higher Education

    Inventor： Kamel Khalili ,  Wenhui Hu

    IPC: A61K38/46 ,  C12N15/11 ,  A61K48/00 ,  A61K9/00 ,  A61K35/12 ,  A61K45/06 ,  C12N7/00 ,  C12N9/22

    Abstract: A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

    Detection of HIV-1-associated neurocognitive disorders
    49.
    发明授权
    Detection of HIV-1-associated neurocognitive disorders 有权

    公开(公告)号：US10161925B2

    公开(公告)日：2018-12-25

    申请号：US15129353

    申请日：2015-03-24

    Applicant: Temple University-Of The Commonwealth System of Higher Education ,  The Johns Hopkins University

    Inventor： Salim Merali ,  Carlos A. Barrerro ,  Kamel Khalili ,  Jay Rappaport ,  Norman J. Haughey ,  Ned Sacktor

    IPC: G01N33/487 ,  G01N30/88 ,  G01N33/53

    Abstract: Provided is a method of detecting mild neurocognitive disturbance (MNCD) or HIV associated dementia (HAD) in a patient comprising detecting the level of acetyl spermine and/or acetyl spermidine from a cerebrospinal fluid test sample of the patient; and comparing the level of acetyl spermine and/or acetyl spermidine in the test sample to the level of the acetyl spermine and/or acetyl spermidine in a cerebrospinal fluid control sample or to a control value for lack of neurocognitive impairment, MNCD or HAD; wherein an elevated level of acetyl spermine and/or acetyl spermidine in the test sample as compared to the level in the control sample or a control value for lack of neurocognitive impairment, or a level of acetyl spermine and/or acetyl spermidine that is similar to that of a control value for MNCD or HAD, indicates that the patient suffers from MNCD or HAD. Also provided are methods for measuring the progression of an HIV-1-associated neurocognitive disorder, as well as methods for staging such a disorder.

Patent Agency Ranking